Abstract
This article has been corrected: The correct affiliation information is given below: 1 Medical Oncology Department, Catalan Institute of Oncology - Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Original article: Oncotarget. 2018; 9:27074-27086. https://doi.org/10.18632/oncotarget.25478.
| Original language | English |
|---|---|
| Pages (from-to) | 2576 |
| Number of pages | 1 |
| Journal | Oncotarget |
| Volume | 10 |
| Issue number | 26 |
| DOIs | |
| Publication status | Published - 1 Apr 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer 8)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver